ArticleBlood2005
Jak3 negatively regulates dendritic-cell cytokine production and survival.
Article in Blood, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Tofacitinib downregulates JAK1 and JAK3 on human intestinal monocytes and macrophages without affecting dendritic cells phenotype or function.Journal of translational autoimmunity · 2025Article
- Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling.Journal of experimental & clinical cancer research : CR · 2024Review
- Plasmacytoid dendritic cells: A dendritic cell in disguise.Molecular immunology · 2023Review
- Selective Inhibitors of Janus Kinase 3 Modify Responses to Lipopolysaccharides by Increasing the Interleukin-10-to-Tumor Necrosis Factor α Ratio.ACS pharmacology & translational science · 2023Article
- Reclassification of plasmacytoid dendritic cells as innate lymphocytes is premature.Nature reviews. Immunology · 2023Article
- Spontaneous Posterior Segment Vascular Disease Phenotype of a Mouse Model, rnv3, Is Dependent on the Crb1rd8 Allele.Investigative ophthalmology & visual science · 2018Article
- Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.Drug safety · 2016Review
- Article
- Upregulation of excitatory amino acid transporters by coexpression of Janus kinase 3.The Journal of membrane biology · 2014Article
- IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism.Mucosal immunology · 2014Article
- The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Ablation of tumor progression locus 2 promotes a type 2 Th cell response in Ovalbumin-immunized mice.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Article
- Targeting innate immunity protein kinase signalling in inflammation.Nature reviews. Drug discovery · 2009Review
- Article
- Janus kinases in immune cell signaling.Immunological reviews · 2009Review
- The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- Role of IL-21 in immune-regulation and tumor immunotherapy.Cancer immunology, immunotherapy : CII · 2007Review
- Transcription factors in the control of dendritic cell life cycle.Immunologic research · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cytokines are critical in regulating the development and function of diverse cells. Janus kinase 3 (Jak3) is a tyrosine kinase expressed in hematopoietic cells that associates with the common gamma chain (gammac) and is required for signaling for a family of cytokines including interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15, and IL-21; deficiency of either Jak3 or gammac results in severe combined immunodeficiency (SCID). While Jak3 is essential for lymphoid-cell development, the potential roles for Jak3 in regulating dendritic cells (DCs) were unclear. Herein, we show that although CD8+CD11c+ splenic DCs are absent in Jak3-/- mice, bone marrow-derived DCs developed normally in vitro from Jak3-/- precursor cells. In fact, the survival of Jak3-/- DCs was enhanced, and they expressed lower levels of proapoptotic proteins. Jak3-/- DCs exhibited normal antigen uptake and up-regulation of costimulatory molecules. However, Jak3-/- DCs produced more IL-12 and IL-10 in response to Toll-like receptor ligands, which correlated with enhanced T helper 1 (Th1) differentiation in vivo. In summary, Jak3 is not essential for DC development but unexpectedly appears to be an important negative regulator. These results may be relevant clinically for patients with SCID who have undergone hematopoietic stem cell transplantation and for patients who might be treated with a Jak3 inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.